The Diaphanous-related formins are effectors for Rho GTPases. Two recent reports have unveiled previously unappreciated activities of Drf3 (mDia2), eliciting cytoskeletal rearrangements at the behest of Cdc42, and of DRF2 (hDia2C), regulating endosome dynamics for RhoD. Further complexity in Drf functions was recently brought to light in a report by Gasman et al. [5] . In an attempt to identify an effector protein that might mediate the actions of the RhoD GTPase on early endosome motility and distribution [14], a splice variant of human DRF2 (designated hDia2C, which somewhat confusingly is the human homologue of mDia3 and not mDia2) was isolated from a HeLa cell cDNA library by yeast two-hybrid methods. Although splice variants of human DRF2 that change the amino acids at the extreme carboxyl terminus after residue 1080 or alter 3' untranslated sequences (generating four possible combinations) had previously been described, the splice variant that bound RhoD was novel. The hDia2C form has two apparently independent changes within the GBD -an alternative splicing event that results in the deletion of amino acids 43-53 and the alteration of residues 54 and 55 from Asp-Val to Lys-Leu, and an additional alternative splice resulting in the insertion of six amino acids after residue 148 (Figure 2) . Active RhoD was able to recruit full-length hDia2C from the cytoplasm to early endosomes where it co-localised with transferrin and Rab5. The ability of RhoD to decrease the number, velocity and track length of motile endosomes could be recapitulated by an aminoterminally deleted, active DRF2 ( Figure 1B) . Moreover, the ability of RhoD to induce these effects was reduced by the specific RNAi-mediated knockdown of
[9]), the biological significance of this interaction in mammalian cells was unknown. Drf1 deletion led to a compensatory elevation of Drf3 in embryoid-bodyderived cell lines, which resulted in increased filopodia, microspikes and lamellipodia, typical actin cytoskeletal responses induced by Cdc42 [10, 11] . Microinjection of a neutralising anti-Drf3 antibody, or expression of an interfering Drf3 mutant, blocked Cdc42-induced actin remodelling. Fluorescence resonance energy transfer (FRET) experiments confirmed that Drf3 and an active Cdc42 mutant interacted in vivo and that Drf3 binding to wild-type Cdc42 in polarised motile fibroblasts occurred predominantly at the leading edge. These experiments substantiate the conclusion that Drf3 is a physiologically relevant effector of Cdc42.
Given the apparent function of Drf3 as a Cdc42 effector, the GBD was scrutinised for a Cdc42-binding region. In fact, Drf3 contains a well conserved CRIB motif, a domain famous for its Cdc42 binding ability [12] . There is little homology in the corresponding region of Drf1, consistent with the inability of this Drf to bind Cdc42 [13] . Mutation of a highly conserved histidine residue within the CRIB domain to aspartic acid blocked Cdc42 binding without affecting Rho binding in yeast two-hybrid assays, and inhibited Cdc42 interaction with Drf3 in vivo as determined by FRET. Thus, the GBD allows Drf3 to alternate as an effector in Rho-or Cdc42-responsive signalling pathways ( Figure 1A) .
Further complexity in Drf functions was recently brought to light in a report by Gasman et al. [5] . In an attempt to identify an effector protein that might mediate the actions of the RhoD GTPase on early endosome motility and distribution [14] , a splice variant of human DRF2 (designated hDia2C, which somewhat confusingly is the human homologue of mDia3 and not mDia2) was isolated from a HeLa cell cDNA library by yeast two-hybrid methods. Although splice variants of human DRF2 that change the amino acids at the extreme carboxyl terminus after residue 1080 or alter 3' untranslated sequences (generating four possible combinations) had previously been described, the splice variant that bound RhoD was novel. The hDia2C form has two apparently independent changes within the GBD -an alternative splicing event that results in the deletion of amino acids 43-53 and the alteration of residues 54 and 55 from Asp-Val to Lys-Leu, and an additional alternative splice resulting in the insertion of six amino acids after residue 148 (Figure 2) . Active RhoD was able to recruit full-length hDia2C from the cytoplasm to early endosomes where it co-localised with transferrin and Rab5. The ability of RhoD to decrease the number, velocity and track length of motile endosomes could be recapitulated by an aminoterminally deleted, active DRF2 ( Figure 1B) . Moreover, the ability of RhoD to induce these effects was reduced by the specific RNAi-mediated knockdown of the hDia2C isoform. These data indicate that DRF2 can function as an effector for RhoD.
With multiple potential binding partners ( In summary, additional signalling pathways converging on Drf proteins as critical effectors have been revealed. Future challenges include determining how Drf proteins contribute to actin filament remodelling and consequently to endosome and cell motility. Our understanding of Drf functions has been somewhat opaque, but recent progress has made some additional roles of these proteins transparently clear.
